VBL Therapeutics (Nasdaq:VBLT) Revenue

Biotechnology Research • Modiin-Maccabim-Reut, Center District, Israel • 11-20 Employees

VBL Therapeutics (Nasdaq:VBLT) revenue & valuation

Annual revenue	$401,000
Revenue per employee	$29,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$1,300,000
Total funding	$16,900,000

Key Contacts at VBL Therapeutics (Nasdaq:VBLT)

Shifra Fain-Shmueli

Director Of Clinical Operations

Livnat Bangio

Director Of Production And Process Development

Company overview

Headquarters	8 Hasatat St., Modiin, Israel 7178106, IL
Phone number	+97289935000
Website	vblrx.com
NAICS	541714
Keywords	Innovation, Biotech / Pharma, Immune-Inflammatory
Founded	2000
Employees	11-20
Socials

VBL Therapeutics (Nasdaq:VBLT) Email Formats

VBL Therapeutics (Nasdaq:VBLT) uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 42.1% of the time.

Format	Example	Percentage
{first name}.{last name}@company.com	john.doe@company.com	42.1%
{first name}@company.com	john@company.com	25.3%
{first name initial}{last name}@company.com	{first name initial}doe@company.com	14.8%
{first name}{last name}@company.com	johndoe@company.com	10.2%
{last name}@company.com	doe@company.com	7.6%

About VBL Therapeutics (Nasdaq:VBLT)

VBL Therapeutics (Nasdaq: VBLT) is developing targeted therapies for immune-inflammatory diseases. VBL’s lead immunology product candidate VB-601 is a targeted antibody for immune-inflammatory applications expected to enter Phase 1 this year that has shown disease-modifying activity across multiple preclinical models including multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease.

Employees by Management Level

Total employees: 11-20

Seniority

Employees

Director

Entry

Head

Employees by Department

VBL Therapeutics (Nasdaq:VBLT) has 5 employees across 4 departments.

Departments

Number of employees

Funding Data

Explore VBL Therapeutics (Nasdaq:VBLT)'s funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2022-01-20	14	$16,900,000

Funding Insights

$16,900,000

Total funding amount

$16,900,000

Most recent funding amount

Number of funding rounds

Frequently asked questions

VBL Therapeutics (Nasdaq:VBLT) is located in Modiin-Maccabim-Reut, Center District, IL.

You can reach VBL Therapeutics (Nasdaq:VBLT) at +97289935000.

VBL Therapeutics (Nasdaq:VBLT) generates an estimated annual revenue of $401,000. This revenue figure reflects the company's market position and business performance in its industry.

VBL Therapeutics (Nasdaq:VBLT) has an estimated valuation of $1,300,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

VBL Therapeutics (Nasdaq:VBLT) was founded in 2000, making it 26 years old. The company has established itself as a significant player in its industry over this time.

VBL Therapeutics (Nasdaq:VBLT) has approximately 11-20 employees. The company continues to grow its workforce to support its business operations and expansion.

VBL Therapeutics (Nasdaq:VBLT) has raised a total of $16,900,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.

Key Contacts at VBL Therapeutics (Nasdaq:VBLT)

Shifra Fain-Shmueli

Director Of Clinical Operations

Livnat Bangio

Director Of Production And Process Development

4.8

40,000 users